DALLAS, Sept. 2, 2021 /PRNewswire/ -- Lantern
Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical
company using its proprietary RADR® artificial
intelligence ("A.I.") platform to transform the cost, pace, and
timeline of oncology drug discovery and development, today
announced the addition of two senior industry executives to support
the Company's clinical and manufacturing initiatives. Dr. Harry
Kochat has been appointed Senior Director of Chemistry,
Manufacturing and Controls (CMC) and Manufacturing Quality Affairs,
where his responsibilities will include oversight of drug candidate
manufacturing and quality control. Darlene Bunpian, MPH has been
appointed Clinical Trial Project Manager, where she will be
responsible for oversight of the planned clinical trials, including
the planned Phase 2 clinical trial of LP-300 as a combination
therapy in never-smokers with Non-Small Cell Lung Cancer
(NSCLC).
![Lantern Pharma (LTRN) Logo (PRNewsfoto/Lantern Pharma) Lantern Pharma (LTRN) Logo (PRNewsfoto/Lantern Pharma)](https://mma.prnewswire.com/media/1216507/Lantern_Pharma_Logo.jpg)
Dr. Kochat brings 30 years of experience with multiple
successful drug candidates and management of teams of all phases
and sizes in CMC, GxP and GLP, as well as quality regulatory
affairs. He has years of hands-on experience authoring, reviewing
and approving GMP quality documents, including 3 oncology NDAs, 4
ANDAs, and 13 preclinical programs, as well as oversight of CMOs
and CROs. Most recently, Dr. Kochat has served as Director,
Pharmaceutical Operations & Business Development at the Plough
Center for Sterile Drug Delivery Solutions (UTHSC), Memphis, where his responsibilities have
included leading all end-to-end operations related to cGMP
manufacturing and quality affairs, including development, site
registration and launch of a sterile, cGMP fill-finish
facility. Dr. Kochat received a Ph.D. degree in Organic
Chemistry from Purdue University,
followed by NIH fellowships at Purdue
University and Rice University,
as well as M.Sc. and B.Sc. degrees in Chemistry from the University
of Kerala, India. Dr. Kochat has
co-invented more than 225 issued domestic and international patents
and co-authored over 65 peer journal scientific publications.
Ms. Bunpian is a seasoned and certified research professional
with 15+ years of experience, including clinical research, project
management, study start up, regulatory submissions, and
budgeting. Most recently, she served as Research Project
Manager and Clinical Research Coordinator with Baylor Scott & White Heath, where she
oversaw clinical trials in various therapeutic areas, including GI
cancer, neurology, rheumatology, and abdominal transplant
research. She has years of hands-on experience in running
industry-sponsored and investigator-initiated clinical trials
according to ICH Good Clinical Practices, as well as federal laws
and regulations. Before transitioning to clinical research, Ms.
Bunpian worked for several years as a Research Associate in gene
expression and DNA sequencing at the University of Texas Southwestern Medical Center and
Lexicon Pharmaceuticals. Ms. Bunpian received a BS degree in cell
and molecular biology from Tulane
University and an MPH degree from the University of Texas School of Public Health.
Ms. Bunpian also holds the ACRP-CP certification through the
Association of Clinical Research Professionals.
Panna Sharma, President & CEO
of Lantern Pharma, stated, "Our entire team welcomes these two
accomplished and experienced industry executives to our leadership
team. Each of them brings a strong track record overseeing and
delivering large drug development initiatives, ensuring they are
completed on time, within budget and to the highest quality
standards that can lead to positive patient impact. We are building
a world-class team to support our anticipated growth, as we execute
on our mission of transforming the cost, risk and timeline of drug
development by leveraging our proprietary RADR® A.I.
platform."
About Lantern Pharma
Lantern Pharma (LTRN) is a
clinical-stage oncology-focused biopharmaceutical company
leveraging its proprietary RADR® A.I. platform and
machine learning to discover biomarker signatures that identify
patients most likely to respond to its pipeline of genomically
targeted therapeutics. Lantern is currently developing four drug
candidates and an ADC program across eight disclosed tumor targets,
including two phase 2 programs. By targeting drugs to patients
whose genomic profile identifies them as having the highest
probability of benefiting from the drug, Lantern's approach
represents the potential to deliver best-in-class outcomes. More
information is available at: www.lanternpharma.com and Twitter
@lanternpharma.
Forward-looking Statements
This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking
statements include, among other things, statements relating to:
future events or our future financial performance; the potential
advantages of our RADR® platform in identifying
drug candidates and patient populations that are likely to respond
to a drug candidate; our strategic plans to advance the development
of our drug candidates and antibody drug conjugate (ADC)
development program; estimates regarding the development timing for
our drug candidates and ADC development program; our research and
development efforts of our internal drug discovery programs and the
utilization of our RADR® platform to streamline the
drug development process; our intention to leverage artificial
intelligence, machine learning and genomic data to streamline and
transform the pace, risk and cost of oncology drug discovery and
development and to identify patient populations that would likely
respond to a drug candidate; estimates regarding potential markets
and potential market sizes; sales estimates for our drug candidates
and our plans to discover and develop drug candidates and to
maximize their commercial potential by advancing such drug
candidates ourselves or in collaboration with others. Any
statements that are not statements of historical fact (including,
without limitation, statements that use words such as "anticipate,"
"believe," "contemplate," "could," "estimate," "expect," "intend,"
"seek," "may," "might," "plan," "potential," "predict," "project,"
"target," "objective," "aim," "should," "will," "would," or the
negative of these words or other similar expressions) should be
considered forward-looking statements. There are a number of
important factors that could cause our actual results to differ
materially from those indicated by the forward-looking statements,
such as (i) the impact of the COVID-19 pandemic, (ii) the risk
that none of our product candidates has received FDA marketing
approval, and we may not be able to successfully initiate, conduct,
or conclude clinical testing for or obtain marketing approval for
our product candidates, (iii) the risk that no drug product based
on our proprietary RADR A.I. platform has received FDA marketing
approval or otherwise been incorporated into a commercial product,
and (iv) those other factors set forth in the Risk Factors section
in our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and
Exchange Commission on March 10,
2021. You may access our Annual Report on Form 10-K for the
year ended December 31, 2020 under
the investor SEC filings tab of our website
at www.lanternpharma.com or on the SEC's website
at www.sec.gov. Given these risks and uncertainties, we can
give no assurances that our forward-looking statements will prove
to be accurate, or that any other results or events projected or
contemplated by our forward-looking statements will in fact occur,
and we caution investors not to place undue reliance on these
statements. All forward-looking statements in this press release
represent our judgment as of the date hereof, and, except as
otherwise required by law, we disclaim any obligation to update any
forward-looking statements to conform the statement to actual
results or changes in our expectations.
CONTACTS:
Investor Relations
David
Waldman, Crescendo Communications, LLC
IR@lanternpharma.com
212-671-1021
Public Relations
Nicholas
Koulermos, Vice President – 5W Public Relations
lantern@5wpr.com
646-843-1812
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lantern-pharma-expands-management-team-with-appointment-of-two-leading-industry-executives-to-support-clinical-and-manufacturing-initiatives-301368440.html
SOURCE Lantern Pharma